The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study

Sleep Disordered Breathing Clinical Trial

— PARS  

Official title:

The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06292299
• Other study ID #: INGN22RM471P
• Secondary ID: 10072600
• Status: Not yet recruiting
• Start date: March 1, 2024
• Est. completion date: December 2025

Study information

• Verified date: February 2024
• Source: NHS Greater Clyde and Glasgow
• Contact: Ross J Langley, MBChB BSc PhD MRCPCH
• Phone: 01414516582
• Email: ross.langley[@]ggc.scot.nhs.uk
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Diagnostic investigations in paediatric respiratory and sleep medicine are often challenging due to patient size (due to prematurity), tolerability, and compliance with "gold standard equipment". Children with sensory/behavioural issues, at increased risk of sleep disordered breathing (SDB), often find tolerating standard diagnostic equipment difficult. There is a need to develop non-invasive, wireless, devices designed for the paediatric population. Devices must address health in-equalities as high-risk children, with low birth weights, genetic syndromes, or complex neuro-disabilities, are often unable to undergo current investigations, particularly in sleep medicine. Prompt and accurate diagnosis of SDB is important to facilitate early intervention and improve outcomes Infants in the neonatal period can have immature breathing control which manifests as excessive central breathing pauses, apnoea's, whilst asleep requiring oxygen therapy. There is also a risk to newborn term infants of sudden unexpected neonatal collapse, even in "low risk" babies. Diagnosis of breathing issues in babies can be challenging since babies are often too small for standard monitoring equipment. Effective monitoring and appropriate treatment of apnoea's has been shown to improve prognosis in terms of 5-year mortality and neurodevelopmental outcomes. This observational study is part of a phased clinical program of research that aims to validate a small wearable biosensor developed by PneumoWave Ltd in a paediatric clinical setting with the overall primary endpoints of monitoring and assessing respiratory pattern as an aid to sleep diagnostics, and as a device to monitor apnoea in neonatal patients.

Description:

Sleep diagnostics The investigation of sleep disordered breathing (SDB) in children can be challenging given the requirement to apply sensors/bands that measure physiological changes as part of a cardiorespiratory sleep study (CR-poly). Children with sensory/behavioural issues, who have an increased risk of SDB, often find tolerability of standard diagnostic equipment difficult. Similarly, the usefulness is limited in low weight infants. Thus, there is a need to investigate novel devices which may provide sleep diagnostic information when a CR-poly may be inappropriate or challenging. A wearable respiratory rate (RR)/effort sensor can provide continuous remote monitoring of patients and may identify abnormal breathing patterns associated with SDB. Central Apnoea & abnormal breathing patterns in neonatal patients Babies born prematurely can often have apnoea of prematurity requiring caffeine therapy. Similarly, term (or term corrected) infants can have immature breathing control which manifests as excessive central breathing pauses whilst asleep requiring oxygen therapy. There is also a risk to newborn term infants of sudden unexpected collapse, even in "low risk" babies. Diagnosis of breathing issues in babies can be challenging since babies are often too small for standard CR-poly equipment. We aim to use the Pneumowave sensor alongside other diagnostic equipment to assess the feasibility of using this novel sensor to aid diagnosis in the post-natal period and pre-discharge from neonatal unit. Currently, newborn infants receive no standard respiratory monitoring following delivery. We aim to use the Pneumowave sensor as an indicator of altered respiratory patterns in this patient group. PneumoWave Ltd Device PneumoWave Ltd is developing a small, chest-worn, ambulatory biosensor ("Pneumowave") to detect changes in a range of respiratory metrics. This physical monitor is linked wirelessly via Bluetooth to a central monitoring systems in the form of a mobile platform app (running on a smartphone or tablet). Real-time data analysis, event detection and alert response management algorithms will eventually be are located in the hub, mobile app - they are currently in the cloud depending on the device configuration. The proposed technology, Pneumowave device, will be used in the diagnosis, treatment and monitoring of illness, and therefore must be regulated as a Class 2 Medical Device in accordance with the regulatory framework in each country of use. To achieve this, PneumoWave Ltd first intends to develop a device capable of detecting adverse respiratory events in the hospital setting where immediate attendance to alerts is available. Further technical development will be required prior to the submission for regulatory approval of a device that is suitable for use in the community where there may be a longer time before a response is activated. This hospital study aims to compare the PneumoWave Ltd monitoring system with the current clinical standard for such monitoring in a range of hospital-based clinical services. The studies will observe three distinct patient groups: Group 1: Patients attending for an overnight CR-poly - A subgroup of these patients will take the Pneumowave device home for extended home-based sleep studies for up to 7 nights. Group 2: Patients who are at risk of apnoea in the neonatal unit

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 150
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Minute to 16 Years

Eligibility

Inclusion Criteria:

Group 1 - CR-poly group

• Patient undergoing overnight CR-poly
• Age birth to >=16 years
• Are willing and able to give informed assent/consent or have available next of Kin to provide informed consent on the participant's behalf
• Able (in the Investigators opinion) to comply with all study requirements
• Can speak and read English Group 2 - Apnoea group
• Inpatient in neonatal unit
• Age birth (from 30 weeks gestational age) to term corrected
• Parents willing and able to give informed consent
• Able (in the Investigators opinion) to comply with all study requirements
• Can speak and read English Exclusion Criteria: Group 1 - CR-poly group
• Unable to provide consent and no next of kin to provide consent on participants behalf
• Treating clinician deems patient inappropriate to be included in study Group 2 - Apnoea group
• No next of kin to provide consent on participants behalf
• Treating clinician deems patient inappropriate to be included in study

Related Conditions & MeSH terms

• Apnea of Prematurity
• Respiratory Aspiration
• Respiratory Rate
• Sleep Apnea Syndromes
• Sleep Disordered Breathing

Intervention

Device:
• Pneumowave
Pneumowave biosensor(s) will be be used to collect data from chest +/- abdominal movement and compared to standard clinical monitoring (e.g. CR-PSG)

Locations

Country	Name	City	State
United Kingdom	Royal Hospital for Children, Glasgow	Glasgow	Glasgow City
United Kingdom	Royal Hospital for Children, Glasgow	Glasgow

Sponsors (2)

Lead Sponsor	Collaborator
NHS Greater Clyde and Glasgow	INNOVATEUK

Country where clinical trial is conducted

United Kingdom, 

References & Publications (6)

Chu M, Nguyen T, Pandey V, Zhou Y, Pham HN, Bar-Yoseph R, Radom-Aizik S, Jain R, Cooper DM, Khine M. Respiration rate and volume measurements using wearable strain sensors. NPJ Digit Med. 2019 Feb 13;2:8. doi: 10.1038/s41746-019-0083-3. eCollection 2019. — View Citation

Folke M, Cernerud L, Ekstrom M, Hok B. Critical review of non-invasive respiratory monitoring in medical care. Med Biol Eng Comput. 2003 Jul;41(4):377-83. doi: 10.1007/BF02348078. — View Citation

Massaroni C, Nicolo A, Lo Presti D, Sacchetti M, Silvestri S, Schena E. Contact-Based Methods for Measuring Respiratory Rate. Sensors (Basel). 2019 Feb 21;19(4):908. doi: 10.3390/s19040908. — View Citation

Ono T, Takegawa H, Ageishi T, Takashina M, Numasaki H, Matsumoto M, Teshima T. Respiratory monitoring with an acceleration sensor. Phys Med Biol. 2011 Oct 7;56(19):6279-89. doi: 10.1088/0031-9155/56/19/008. Epub 2011 Sep 6. — View Citation

Voscopoulos C, Brayanov J, Ladd D, Lalli M, Panasyuk A, Freeman J. Special article: evaluation of a novel noninvasive respiration monitor providing continuous measurement of minute ventilation in ambulatory subjects in a variety of clinical scenarios. Ane — View Citation

Williams GW 2nd, George CA, Harvey BC, Freeman JE. A Comparison of Measurements of Change in Respiratory Status in Spontaneously Breathing Volunteers by the ExSpiron Noninvasive Respiratory Volume Monitor Versus the Capnostream Capnometer. Anesth Analg. 2 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the feasibility of collecting respiratory waveform data using Pneumowave device in patients who have (1) attended the sleep laboratory for CR- polysomnography and (2) are inpatient in neonatal unit	1) Length of time device in situ on patient 2) Number of times device removed by patient / other 3) Ability of device to collect data while in situ	2 years
Secondary	Collate respiratory data in patients who have attended the sleep laboratory for CR- poly or inpatient in neonatal unit. Respiratory data will observe: (1) Normal respiratory effort (2) Response to treatments	(1) Observation of waveform data from Pneumowave device and compare to: normal care vital signs and continuous monitoring vital signs extracted from patient monitors. (2) Compare Pneumowave respiratory wave patterns to clinical events: normal respiratory patterns and clinical deterioration	2 years
Secondary	Collate waveform and motion artefact data in patients who have attended overnight CR-polysomnography	Compare respiratory waveform patterns and motion artefact data to: banded sleep diagnostic information	2 years
Secondary	Collate waveform and motion artefact data in neonatal patients at risk of central apnoea	(1) Observation of waveform data from Pneumowave device and compare to: normal care vital signs, continuous monitoring vital signs extracted from patient monitors (2) Compare Pneumowave respiratory wave patterns to clinical events: normal respiratory patterns, clinical deterioration ,Interventions in neonatal unit	2 years
Secondary	Assess the useability of Pneumowave in the opinion of the clinician, nurse and patient	Interview of the stakeholders on the useability of the device: Clinician, Nurse, Patient (if able to)	2 years